Madrigal Pharmaceuticals, Inc.

NASDAQ (USD): Madrigal Pharmaceuticals, Inc. (MDGL)

Last Price

340.14

Today's Change

+15.43 (4.75%)

Day's Change

313.72 - 346.04

Trading Volume

458,381

Profile
MDGL

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. William J. Sibold Mr. William J. Sibold

Full Time Employees:  376 376

IPO Date:  2007-02-06 2007-02-06

CIK:  0001157601 0001157601

ISIN:  US5588681057 US5588681057

CUSIP:  558868105 558868105

Beta:  -0.47 -0.47

Last Dividend:  0.00 0.00

Dcf Diff:  334.98 334.98

Dcf:  -0.92 -0.92

Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Address

Four Tower Bridge,
West Conshohocken, PA 19428, US

267 824 2827

http://www.madrigalpharma.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment